RecruitingDrug trialUsing Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLCTo test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.